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Background: Acetaminophen toxicity is the most common form of acute liver failure in the U.S. After acetaminophen overdoses, quantitation of
plasma acetaminophen can aid in predicting severity of injury. However, recent case reports have suggested that acetaminophen concentrations
may be falsely increased in the presence of hyperbilirubinemia.
Methods: We tested sera obtained from 43 patients with acute liver failure, mostly unrelated to acetaminophen, utilizing 6 different acetaminophen
quantitation systems to determine the significance of this effect. In 36 of the 43 samples with bilirubin concentrations ranging from 1.0–61.5 mg/dl no
acetaminophenwas detectable by gas chromatography-mass spectroscopy. These 36 samples were then utilized to test the performance characteristics of
2 immunoassay and 4 enzymatic–colorimetric methods.
Results: Three of four colorimetric methods demonstrated ‘detectable’ values for acetaminophen in from 4 to 27 of the 36 negative samples, low
concentration positive values being observed when serum bilirubin concentrations exceeded 10 mg/dl. By contrast, the 2 immunoassay methods
(EMIT, FPIA) were virtually unaffected. The false positive values obtained were, in general, proportional to the quantity of bilirubin in the sample.
However, prepared samples of normal human serum with added bilirubin showed a dose–response curve for only one of the 4 colorimetric assays.
Conclusions: False positive acetaminophen tests may result when enzymatic–colorimetric assays are used, most commonly with bilirubin
concentrations N10 mg/dl, leading to potential clinical errors in this setting. Bilirubin (or possibly other substances in acute liver failure sera)
appears to affect the reliable measurement of acetaminophen, particularly with enzymatic–colorimetric assays.
© 2008 Published by Elsevier B.V.Open access under CC BY-NC-ND license.Keywords: Acetaminophen toxicity; Immunoassay; Colorimetric assay; Bilirubin1. Introduction
Blood concentrations of acetaminophen [or N-acetyl-para-
aminophenol (APAP)] are used routinely to predict the
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Open access under CC BY-NC-ND phen overdoses and to identify acetaminophen use in patients
with acute liver injury when the history is unclear. In cases of
acetaminophen overdose at a single point in time, the Rumack–
Matthew nomogram is helpful in determining the likelihood of
significant hepatotoxicity as a function of acetaminophen
concentration and time post-ingestion [1] In patients admitted
with acute liver failure (ALF), hepatic encephalopathy often
precludes an accurate history and the acetaminophen assay has
been used to ascertain whether acetaminophen has been taken
[2]. In such patients, any concentration of acetaminophen mightlicense.
Table 1
Overall study group characteristics, n=43
Age (median, range) 39, 20–71
Gender (%M/%F) 51/49
Admission total bilirubin, mg/dl (median, range) 18.3, 1.4–61.5
Admission ALT, IU/l (median, range) 1.154, 29–9.967
Admission INR (median, range) 2.6, 1.2–10.1
Survival (%) 72
Transplanted (%) 28⁎
⁎No transplanted patients died during the study period.
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antidote for acetaminophen poisoning, should be given [3]. In
either situation, rapid accurate determinations of acetaminophen
concentration are required to assess the need to give NAC in a
timely fashion.
We recently identified 2 patients with positive acetamino-
phen concentrations (i.e., greater than the lower limit of
detection (LLD) of the acetaminophen assay used) in whom
severe liver damage was ultimately found to be due to other
causes. In both cases, acetaminophen concentrations were later
attributed to the possible interference of bilirubin in the assay
used to quantify acetaminophen concentration. 2 recent case
reports have shown similar results [4,5].
In this study, we evaluated systematically the likelihood of
false positive values of serum acetaminophen concentration by
testing 36 acute liver failure sera, once gas chromatography-
mass spectrometry (GC-MS) had excluded the presence of any
amount of the drug, utilizing 6 commonly used acetaminophen
methods. We further examined whether purified bilirubin per
se, when added to normal serum, affected the assay in similar
fashion.Table 2




Assay type EMIT Colorimetric
Reaction mode Rate Rate
Enzyme G6PDH AAA
Chromogen activator a n.a. o-cresol-periodate
Sample volume, μL 3 10
Reaction
Time, Min 1.2 10
Temp, °C 37 37
Reaction product NADH INDP
Primary λ, nm 340 600
Secondary λ, nm 410 800
No. of calibrators (concentration range) 6 (0–200) 2 (0, 300)
LLD, μg/ml 0.12 1.2
No interference b at [TBili, mg/dl] N 30 28
Abbreviations: EMIT, enzyme-multiplied immunoassay technique; G6PDH, gluco
adenine dinucleotide (reduced form) INDP, indophenol; H, Hitachi; FPIA, fluoresce
temperature; LLD, lower limit of detection; [TBili, mg/dl], total bilirubin concentra
a We prefer the term “chromogen activator” over “catalyst,” the term used in the m
enzymes are catalysts.
b Less than 10% error in measured acetaminophen concentration.2. Case 1
A 71-y-old woman complaining of nausea, vomiting and
jaundice for 2 weeks was admitted to hospital with a total serum
bilirubin concentration of 34.8 mg/dl. She denied taking any
acetaminophen while she was fully alert. Serologic testing
indicated acute hepatitis A (positive anti-HAV IgM) as the
cause of her ALF. An acetaminophen concentration was
measured initially at 14.2 μg/ml; however, the acetaminophen
concentration did not decline but remained in the same range
(12.8–16.8 μg/ml) on daily testing over a week's time. A 1:1
dilution of the patient's serum sample with physiological saline
yielded an undetectable acetaminophen result, confirming that her
previous acetaminophen concentrations likely represented false
positive values. Despite her history, she was given NAC on the
basis of the ‘detectable’ acetaminophen concentration; she
recovered slowly over the next 14 days.
3. Case 2
A 49-y-old man with ALF of unknown cause was admitted
to Walter Reed Army Medical Center with altered mentation
and a total serum bilirubin concentration of 28 mg/dl. Based on
an acetaminophen concentration of 30 μg/ml he was given
NAC. The patient did not improve and continued to have
positive acetaminophen concentrations on several occasions
over a 3 week hospitalization. Based on liver biopsy, he was
diagnosed with severe autoimmune hepatitis and begun on
prednisone and azathioprine therapy with good improvement.
Similar to Case 1, repeat acetaminophen testing using a 1:1
dilution of this patient's serum sample yielded no detectable
acetaminophen.FPIA THQ INDP-D Stanbio
AxSym Vitros 950 Dimension RXL AU400
FPIA Colorimetric Colorimetric Colorimetric
Endpoint Endpoint Endpoint Rate
n.a. AAA AAA AAA
n.a. Ferricyanide o-cresol o-cresol-periodate
150 10 4 100
14 5 10 10
34 37 37 37
n.a. Dye INDP INDP
n.a. 670 600 615
n.a. n.a. 700 n.a
6 (0–200) 3 (10, 95, 330) 3 (0, 75, 300) 1 (300)
1.0 10 2.0 10
10 20 20 10
se-6-phosphate dehydrogenase; AAA, arylacylamidase; NADH, nicotinamide
nce polarization immunoassay; THQ, tetrahydroquinoline; D, dimension; temp,
tion in units of mg/dl; λ, wavelength; n.a., not applicable.
anufacturer's product insert for reactions involving enzymes-substrates because
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4.1. Specimens and subjects
The Acute Liver Failure Study Group began in 1998 to collect detailed
prospective information and serum samples on patients with this rare condition [6].
Serum samples from 43 patients enrolled in the U.S. Acute Liver Failure Study
(including case 1 above) were selected for study to represent patients with varying
severity of liver injury, varying diagnoses and a range of bilirubin concentrations.
All samples and clinical data had been obtained after informed consent fromnext of
kin according to local IRBguidelines at sites participating in theALFStudyGroup.
Sera had been stored at −70 °C prior to use in this analysis. Samples selected were
from patients with acute viral hepatitis (n=25), acetaminophen-induced
hepatotoxicity (n=7), ischemic hepatopathy (n=1), idiosyncratic drug-induced
liver injury, (n=5), or of indeterminate cause (n=5) using previously defined
clinical criteria. Patients with acetaminophen-induced hepatotoxicity and acute
liver failure had awell-defined history of acetaminophen overdose (large ingestions
reported) and very high aminotransferase concentrations. All represented lateFig. 1. Apparent effect of total bilirubin concentration on acetaminophen measurem
various methods/instruments: EMIT/AU400 (A); AAA-INDP/Dimension (B); AAA-T
(F). Abbreviations are the same as in Table 1. Horizontal dotted line represents LL
concentration cited by manufacturer as providing b10% error in measured acetaminop
line (y=0.2707x+1.7125; r=0.9566). Note differences in scale of y-axis between ppresentations with severe liver failure as opposed to early after ingestion, so
acetaminophen concentrations would be expected to be low or undetectable.
Bilirubin concentrations in the overall group ranged from 1.0 mg/dl to 61.5 mg/dl
and included 34 with bilirubin concentrations N10 mg/dl (Table 1).
4.2. Acetaminophen testing
All 43 serum samples were tested for acetaminophen initially by gas
chromatography with nitrogen/phosphorous flame ionization detection (GC-
NPD). The identification of acetaminophen in the positive samples was
confirmed by gas chromatography-mass spectrometry (GC-MS). Both GC-NPD
and GC-MS procedures were developed and validated for this study. Using this
technique, seven sera were determined to contain acetaminophen above the limit
of detection for the GC assays (1 μg/ml) and excluded from further study.
Subsequently, the 36 remaining acetaminophen-negative samples were
submitted for testing utilizing 6 different assay techniques at hospitals affiliated
with or in close proximity to our center. The methods/instruments used were:
EMIT-AU400 (Olympus America Corp, Irving, TX), Hitachi (Rocheents in serum samples from 36 patients with acute liver failure assayed using
HQ/Vitros 250 (C); FPIA/AxSym (D); AAA-INDP/Hitachi (E); Stanbio/AU400
D for each acetaminophen assay; vertical dotted line represents total bilirubin
hen concentration; and, solid line in panel C is the linear least-squares regression
anels.
27J. Polson et al. / Clinica Chimica Acta 391 (2008) 24–30Diagnostics, Indianapolis, IN), AxSym (Abbott, Abbott Park, IL), Vitros 950
(Ortho-Clinical Diagnostics, Rochester, NY), Dimension RXL (Dade Behring,
Newark, DE), and Stanbio (Stanbio Laboratory, Boerne, TX)-AU400 (Table 2).
The characteristics of the assays are shown in detail in Table 2.
4.3. Preparation of samples supplemented with bilirubin
To specifically evaluate the role of bilirubin concentration as the cause of the
detectable apparent acetaminophen concentration in the various acetaminophen
assays, we prepared normal human serum samples supplemented with
unconjugated bilirubin (Sigma, Baltimore, MD) to achieve final bilirubin
concentrations at or near 0, 1, 2, 5, 9, 13, 18, 26, 34 and 38 mg/dl. We then
submitted these samples for testing by the 4 colorimetric assays. Calculated
bilirubin concentrations obtained in the sera tested were independently
confirmed by standard biochemical testing for the samples used (modified
diazo method for quantification of bilirubin concentration in the Olympus
AU400 chemistry analyzer, with a lower limit of linearity=0.08 mg/dl.
4.4. Statistical methods
Pearson product moment correlational analysis was used to predict apparent
acetaminophen concentration from the total bilirubin concentration when the
relationship between these variables appeared linear. Spearman rank order
correlation (rho) was used when the relationship was non-linear. We used box-
and-whisker plots to evaluate the effect of a total bilirubin concentration
N10 mg/dl on apparent acetaminophen concentration; outliers in box-and-
whisker plots were defined as values that were smaller than the lower quartile
minus 1.5 times the interquartile range, or larger than the upper quartile plus 1.5
times the interquartile range (inner fences of central box in box-and-whisker
plot). Mann–Whitney tests were used to study the influence of total bilirubin
concentration N10 mg/dl on apparent acetaminophen concentration. SPSS V14
was used to perform all statistical analyses and box-and-whisker plots were
made with MedCalc software (Mariakerke, Belgium).
5. Results
5.1. Acetaminophen concentration by GC-NPD and GC/MS
Acetaminophen was undetectable by GC-NPD in 36/43
samples. Among the 7 samples that were positive forFig. 2. Extent of increased acetaminophenmeasurements in serum samples (n=36) from
and upper lines in the central box represent the 25th and75th percentile values of the data
the lowest to the highest value in the data set, excluding outliers. Outliers are displayed asacetaminophen, 5 were from patients with acetaminophen-
induced ALF, and 2 were from patients with ALF secondary to
acute hepatitis B. Among the 7 acetaminophen patients
diagnosed clinically as acetaminophen-related, 5 were positive
as noted, and 2 were negative by GC-MS, possibly due to the
long interval (~72 h) between ingestion and obtaining serum for
storage. The 7 samples that were positive for acetaminophen by
GC-NPD and GC-MS were excluded from further testing.
5.2. Effect of ALF sera on measured acetaminophen
concentration by various methods/instruments
Four of the six assay methods demonstrated frequent false
positive results (i.e., values of acetaminophenN the method-
specific LLD), varying from 4/36 to 27/36 positive samples
depending upon the method employed (Fig. 1). The EMIT
(immunoassay) and AAA-INDP-D methods (colorimetric) were
essentially unaffected (Fig. 1A and B). The FPIA method
(immunoassay) demonstrated a very low concentration (b3μg/ml
apparent acetaminophen concentration), and therefore clinically
insignificant, likely non-specific interference in 15/36 (42%)
serum samples (Fig. 1D). The three acetaminophenmethods most
affected by increased concentrations of bilirubin in serum samples
from patients with ALF were colorimetric methods (Stanbio, 23
positive, AAA-INDP-H 27 positive, and AAA-THQ 14 positive);
Each of these 3 methods includes an oxidizing agent (i.e.,
periodate or ferricyanide) as a chromogen activator (Table 1 and
Fig. 1C, E and F). Fig. 2 demonstrates the extent to which the
acetaminophen assay was affected in the 3 remaining colorim-
etric acetaminophen methods. The Mann–Whitney test was used
to compare concentrations of total bilirubin concentrations
(b10 mg/dl versusN10 mg/dl for each method (Table 3). Total
bilirubin concentration did not significantly influence apparent
acetaminophen concentration by the EMIT, FPIA andAAA-INDP-
D assays, whereas the apparent acetaminophen concentration bypatients with acute liver failure. Abbreviations are the same as in Table 1. The lower
set, while themiddle line represents themedian value. The vertical line extends from
separate points (empty squares). The asterisk⁎ denotes statistically significant effect.
Table 3




≤10 mg/dl (n=5) N10 mg/dl (n=31)
Average rank Median Minimum Maximum Average rank Median Minimum Maximum p-value
EMIT 17.2 0 0 0.02 18.71 0 0 0.05 0.7902
INDP-H 4.5 0 0 0 20.76 10 0 37 0.0002
FPIA 11 0 0 0 19.71 0 0 2.5 0.0911
THQ 3 0 0 4.6 21 9.3 5.7 18.5 b0.0001
INDP-D 24.7 0 0 4.3 17.5 0 0 0 0.161
Stanbio 4.8 2 0 7.4 20.71 14.1 2.3 53.8 0.0004
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be influenced greatly by hyperbilirubinemia particularly those
samples containingN10mg/dl total bilirubin concentration (Fig. 2).
The effect of increasing bilirubin concentration on acetaminophen
values by the AAA-THQ method was linear, highly correlated
(r=0.96), and consistent with a 27% increase in apparent
acetaminophen concentration for every 1 mg/dl increase in
bilirubin concentration (Fig. 1C and Table 4). The Spearman
rank order correlations for AAA-INDP-H (rho=0.87, pb0.0001)
and FPIA (rho=0.65,pb0.0001) with bilirubin concentrationwere
also found to be highly correlated.
5.3. Effect of bilirubin on acetaminophen concentration in
healthy human sera
Of the four assay systems tested with the bilirubin-
supplemented samples, the Dimension assay did not report
any positive acetaminophen concentrations at increasing
concentrations of bilirubin in healthy human sera, with the
exception of a barely detectable concentration (just below the
lower limit of detection) at the highest concentration of bilirubin
(38 mg/dl). The Hitachi and Stanbio assays, both of which
showed false positive acetaminophen concentrations in many
ALF sera, did not report a single positive acetaminophen
concentration in these healthy human sera regardless of
bilirubin concentration. However, the Vitros assay reported
false positive acetaminophen concentrations which increased in
proportion to increasing concentrations of bilirubin in the
normal human sera as follows: no acetaminophen detected up to
13 mg/dl bilirubin, 10 μg/ml APAP detected at 18 mg/dl
bilirubin, 13 μg/ml APAP at bilirubin 26 mg/dl, 16 μg/ml APAP
at bilirubin 34 mg/dl, and 20 μg/ml APAP at bilirubin 38 mg/dl.Table 4






THQ 0.96 b0.0001 a
INDP-D −0.40 0.0167
Stanbio 0.52 0.0011
a Pearson product moment correlation.6. Discussion
Our study suggests that false positive acetaminophen results
occur quite commonly when testing serum samples from
patients with severe liver injury. Bilirubin appeared to be the
most likely candidate to interfere with acetaminophen assays
causing false positive results and the association with the
colorimetric assays we used would seem to confirm this.
However, the nature and performance characteristics of this
interference have not been fully determined. We chose 6
different assays commonly in use that, according to a College of
American Pathologists external proficiency survey, represent
the methods of choice in approximately 70% of U.S. clinical
laboratories [7]. All were readily available in hospital
laboratories in and around the UT Southwestern medical
complex. We frequently observed positive values in our 36
proven negative samples with all 4 colorimetric methods to
varying degrees, depending on the method. However, the
impact of increasing total bilirubin concentration on reported
acetaminophen concentration in ALF sera was linear only for 1
method: AAA-THQ on the Vitros instrument (Fig. 1C). This
method is the only one employing the ferricyanide reagent. It
may be that ferricyanide plus serum components (bilirubin or
others) yield a suitable byproduct that absorbs at or near the
primary wavelength (λ=670 nm) of the intended “dye” product
(undefined in the manufacturer's product insert), formed during
the AAA-THQ reaction. This same assay was the only one that
performed in a nearly linear fashion when healthy human sera
with added bilirubin were tested, supporting the concept that
bilirubin (or its byproducts) may be the interfering factor in
acetaminophen measurement at least for this particular assay.
Unconjugated and conjugated bilirubin have an absorption peak
between 390 and 460 nm [8]. Therefore, the fact that the
chemical methods most affected by bilirubin interference use a
primary or secondary acetaminophen measurement wavelength
[600–800 nm (Table 2)] considerably higher than 460 nm lends
additional support to the idea that bilirubin byproducts, and not
bilirubin (unconjugated or conjugated) itself, are a likely cause
of the increased acetaminophen values observed in acetamino-
phen assays most affected by bilirubin interference.
That the 3 other assays did not demonstrate as robust
linearity and did not seem affected when normal serum with
added bilirubin was tested, suggests that other interfering
substances are important in these three assays systems although
a partial role for bilirubin cannot yet be excluded.
29J. Polson et al. / Clinica Chimica Acta 391 (2008) 24–30As might be expected if bilirubin were the culprit, immuno-
assay methods (EMIT, FPIA) that do not involve a color
reaction were unaffected by samples containing high concen-
trations (up to 60 mg/dl) of bilirubin; we did not test them
further with the spiked bilirubin sample technique (Fig. 1).
Since a chemical reaction is not required in these assays,
immunoassay methods are less prone to non-specific inter-
ference from endogenous substances either present in human
serum or created as reaction byproducts in the colorimetric
methods that might absorb at or near the primary and/or
secondary absorbance wavelengths. Our data shows that the
extent to which byproducts are either present or created varies
between serum samples from different patients with ALF
because in several instances samples from 2 different patients
with nearly identical total bilirubin concentrations produced
disparate results (one positive, one negative) when each was
tested by the same acetaminophen assay (Fig. 1). This provides
further support that for the conclusion that other as yet
unidentified non-bilirubin substances must be present in
serum from patients with ALF to explain these findings.
As noted, a great deal of variation in the effect on apparent
acetaminophen concentration was observed between the 4
colorimetric methods with increasing total bilirubin concentration
in ALF sera. For example, the AAA-INDP method in the
Dimension instrument showed no apparent effect of increasing
total bilirubin concentration (Fig. 1B) while the Hitachi
instrument showed a substantial effect (Fig. 1E). The difference
between these 2 methods may be due to varying role of the
oxidizing agent, periodate, with o-cresol and varying samples
volumes between the 2 methods (Table 2). For example, the
AAA-INDP method in the Dimension instrument did not appear
to be affected by increasing total bilirubin concentration because,
compared to the AAA-INDP method in the Hitachi instrument,
Dimension uses a relatively small sample volume (4 μl), the o-
cresol reagent in this method is not combined with periodate; in
addition, the reaction mode is endpoint instead of rate. It is of
interest that theAAA-INDPacetaminophenmethodmost affected
by increased concentrations of bilirubin in ALF sera was the
Stanbio method, which uses periodate and the highest serum
sample volume (100 μL) of all acetaminophen methods that we
tested (Table 2). Similarly, the use of an oxidizing agent (i.e.,
ferricyanide), a chromogen activator (i.e., THQ) other than o-
cresol-periodate, and the highest primary measurement wave-
length (λ=670 nm) of all acetaminophen methods that we tested
may explain the differences and substantial effect of increasing
total bilirubin concentration on apparent acetaminophen concen-
tration between the AAA-THQ method and other methods that
are also based on the AAA reaction (Table 2).
Interestingly, neither the Hitachi nor the Stanbio assays (both
colorimetric methods, both apparently affected by increased
bilirubin concentrations in ALF sera) reported false positive
APAP concentrations with increased bilirubin concentrations in
healthy human sera. This finding seems to confirm that, at least
for these assays, that bilirubin itself may not be the interfering
factor, but rather may simply correlate with the concentration of
another substance or substances present in sera from patients
with severe liver injury.In ALF samples, we observed 2 distinct outliers with the
AAA-INDP-D method; however, visual inspection of the data
in Figs. 1B and 2 for the AAA-INDP-D acetaminophen method
clearly indicates that the bulk (34/36 data points) of the apparent
acetaminophen values by this method was less than the lower
limit of detection (2.0 mg/l) for this method. Although it is
difficult to explain the 2 outlier values for apparent acetami-
nophen concentration in Fig. 1B, both of these values occurred
in samples containing relatively low (1.0 mg/dl and 2.0 mg/dl)
total bilirubin concentration and the magnitude of the apparent
acetaminophen concentration in these samples was also low
(1.8 μg/ml and 4.3 μg/ml) and clinically insignificant. The
presence of other interfering substances in larger quantities in
these 2 samples would explain these results. Moreover, 2 of the
acetaminophen methods (AAA-INDP-D and AAA-INDP-H)
(Fig. 1B and E) that we evaluated were based on the same
reaction principle, yet only one of these methods (AAA-INDP-
H; Fig. 1E) demonstrated a substantial effect of bilirubin on
apparent acetaminophen concentration.
Our findings confirm the results of prior papers reporting the
potential for false positive acetaminophen results when hyperbi-
lirubinemic sera are assayed by various methods, [4,5] especially
colorimetrically-based assays, and they broaden the understand-
ing of this phenomenon in several ways. First, we tested serum
samples from a large number of patients with liver injury from a
variety of causes and a broad range of bilirubin concentrations up
to ∼60 mg/dl. We demonstrated that the relationship between
apparent acetaminophen concentration and bilirubin concentra-
tion can approach linearity with some assays but is much less
predictable using most methods. We demonstrated that 3 of the 6
most commonly used acetaminophen assays were markedly
affected by sera from patients with liver injury and increased
bilirubin concentrations. This finding underscores the potential
for the widespread occurrence of false positive acetaminophen
concentrations that at least correlate with the presence of, but are
not necessarily caused by, high serum bilirubin concentrations.
The finding that only one of the assays appears to be affected
specifically by bilirubin, as opposed to other substances present in
acute liver injury sera, raises the intriguing question of what these
other substances may be.
The limitations of this study were that we did not examine
the effect of adding acetaminophen to hyperbilirubinemic sera;
however, most patients with acetaminophen overdoses have a
normal or only mildly increased bilirubin concentration at the
time of presentation [7]. In this way, the quantitation of
acetaminophen in cases of severe acute toxicity is not likely to
be affected, since bilirubin concentrations immediately follow-
ing the acute ingestion are normal or minimally increased.
Bertholf et al. demonstrated a small but measurable effect of
bilirubin (b10%) on the acetaminophen concentration observed
in the toxic (50–150 μg/ml) dose range, and this is mentioned in
some package inserts for these assays [4]. Secondly, our study
does not address true prevalence of false positive acetamino-
phen results in patients with liver injury and hyperbilirubinemia.
Nevertheless, our findings demonstrate that false positive
acetaminophen results occur commonly but vary considerably
between assays, ranging from 0% (EMIT) to 69% (Stanbio).
30 J. Polson et al. / Clinica Chimica Acta 391 (2008) 24–30Since virtually all patients seen within the first 48 h of an
acute acetaminophen overdose have only mildly increased
bilirubin concentrations [9], it is unlikely that false positive
acetaminophen results will occur in the setting of early acute
acetaminophen toxicity, where the quantitative assay is most
useful. However, in any patient with acute liver injury of
unknown etiology and no clear history of acetaminophen use,
clinicians may wish to, but should not rely on, a low-positive
acetaminophen concentration as indicative of acetaminophen-
induced liver injury, particularly when serum bilirubin con-
centrations are high. Use of N-acetyl cysteine, though relatively
safe, has not been shown to be effective to date in non-
acetaminophen liver failure—a randomized blinded trial is
currently under way using intravenous N-acetyl cysteine for
non-acetaminophen patients [10]. A search for etiologies other
than acetaminophen toxicity should continue to be pursued in
patients with signs and symptoms of acute hepatic dysfunction
and hyperbilirubinemia who have low-positive acetaminophen
concentrations particularly when based upon an enzymatic–
colorimetric assay.
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